The Tobacco Industry After Cigarettes: What Does a Post-Combustion Company Look Like?
Philip Morris says it wants to 'unsmoke the world.' If it succeeds, what kind of company will it become—and can it be trusted to manage the transition it claims to be leading?
Imagine Philip Morris International in 2040, assuming its 'smoke-free' transformation succeeds. The company no longer sells combustible cigarettes—or sells them only in a handful of residual markets, representing a single-digit percentage of revenue. Its primary products are nicotine pouches, heated tobacco devices, and pharmaceutical-grade nicotine formulations. Its marketing emphasizes reduced risk, consumer choice, and harm reduction. Its sustainability reports document declining carbon footprints and improved public health outcomes. It sponsors public health research, partners with cessation services, and positions itself as a responsible corporate citizen contributing to the end of the smoking epidemic. Is this scenario a public health triumph—the successful transformation of the world's deadliest industry—or a public health nightmare—the same company that caused the epidemic now profiting from the transition away from it?
The optimistic scenario: the company's transformation is genuine and comprehensive. It has recognized that combustible cigarettes are a declining product category, that its long-term viability depends on transitioning to reduced-risk products, and that the transition can be profitable as well as ethical. It has invested billions in reduced-risk product development, acquired the leading brands in emerging categories (Zyn, nicotine pouches), and accepted—even advocated for—regulation that creates a level playing field and accelerates the transition. In this scenario, the company earns its social license by genuinely contributing to the end of the smoking epidemic. The transformation is real, and the company deserves credit for leading it.
The pessimistic scenario: the transformation is a strategic diversification, not a genuine transition. The company continues to profit from combustible cigarettes in LMICs while promoting its 'smoke-free' credentials in high-income markets. The reduced-risk products complement rather than replace cigarettes—dual use is common, and the company has no incentive to encourage complete switching because it profits from both product categories. The transformation narrative is primarily a public relations strategy: it maintains access to capital (ESG investors), protects against regulation (the company can argue it's already transitioning), and positions the company for a future where cigarettes are less profitable—without requiring the company to sacrifice current cigarette profits. In this scenario, the transformation is a mirage, and the company's contribution to public health is net negative.
The evidence to date supports elements of both scenarios. The company's investment in reduced-risk products is genuine and substantial—the acquisition of Swedish Match for $16 billion was not a PR gesture. The shift in revenue composition—non-combustible products rising from less than 5% to nearly 40% of PMI's revenue in a decade—is real and accelerating. But the company's continued expansion of cigarette sales in LMICs, its opposition to tobacco control measures that would accelerate the transition (taxation, advertising bans), and its resistance to independent post-market surveillance of its reduced-risk products are all consistent with the pessimistic scenario. The company's behavior sends mixed signals because its interests are mixed: it profits from both cigarettes and reduced-risk products, and the transition threatens the former while promising the latter.
The regulatory framework is the decisive variable. In a regulatory environment that makes reduced-risk products more profitable than cigarettes—through differential taxation, honest risk communication, and cigarette-specific restrictions—the company's commercial interests align with the public health interest. In a regulatory environment that treats all nicotine products as equivalent—or that restricts reduced-risk products more heavily than cigarettes—the company's interests align with maintaining cigarette sales. The transformation narrative is not inherently false or true. It's contingent on the regulatory environment in which the company operates. The question is not whether the company can be trusted to manage the transition voluntarily. It's whether the regulatory framework creates incentives that make the transition the most profitable strategy.
The trust question remains fundamental. Even if the regulatory framework aligns the company's interests with public health, the company's history of deception—decades of denying the harms of smoking, manipulating nicotine delivery, marketing to youth—cannot be erased. The company that spent the 20th century perfecting the art of selling addictive, lethal products cannot simply declare itself transformed and expect trust. Trust must be earned through behavior, not claimed through marketing. The company can earn trust by: voluntarily withdrawing cigarettes from markets where reduced-risk alternatives are available, supporting rather than opposing independent research and post-market surveillance, accepting product standards and marketing restrictions that prioritize public health over profit, and being transparent about its continued cigarette sales and the populations they affect. So far, no tobacco company has met these standards.
The tobacco industry after cigarettes will be whatever the regulatory framework and the market make it. It can be a genuine contributor to the end of the smoking epidemic, or it can be the primary obstacle to that end. The difference is not the company's rhetoric. It's the regulatory environment that shapes the company's incentives. The transformation narrative that PMI and its peers are promoting is not a description of reality. It's a bet on a particular regulatory future—a future where reduced-risk products are more profitable than cigarettes. Whether that bet pays off, for the companies and for public health, depends on the decisions made by regulators, policymakers, and the public in the coming years. The company is ready to transform—if transformation is profitable. The question is whether we'll make it so.
